New York State Teachers Retirement System Reduces Holdings in Revvity, Inc. (NYSE:RVTY)

New York State Teachers Retirement System reduced its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 3.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 117,213 shares of the company's stock after selling 4,737 shares during the quarter. New York State Teachers Retirement System owned about 0.09% of Revvity worth $12,291,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Czech National Bank boosted its position in shares of Revvity by 0.5% in the first quarter. Czech National Bank now owns 21,713 shares of the company's stock valued at $2,280,000 after acquiring an additional 99 shares during the period. TriaGen Wealth Management LLC raised its stake in Revvity by 2.3% in the second quarter. TriaGen Wealth Management LLC now owns 4,767 shares of the company's stock valued at $500,000 after purchasing an additional 107 shares in the last quarter. Guinness Asset Management LTD raised its stake in Revvity by 3.3% in the second quarter. Guinness Asset Management LTD now owns 3,587 shares of the company's stock valued at $376,000 after purchasing an additional 116 shares in the last quarter. Inspire Investing LLC raised its stake in Revvity by 2.9% in the first quarter. Inspire Investing LLC now owns 4,190 shares of the company's stock valued at $440,000 after purchasing an additional 117 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in Revvity by 3.6% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,899 shares of the company's stock valued at $409,000 after purchasing an additional 135 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Citigroup raised their target price on shares of Revvity from $135.00 to $145.00 and gave the company a "buy" rating in a research note on Tuesday, July 30th. Leerink Partnrs raised shares of Revvity to a "strong-buy" rating in a research note on Monday, July 8th. Barclays lifted their price target on shares of Revvity from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. lifted their price target on shares of Revvity from $105.00 to $120.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 30th. Finally, TD Cowen lifted their target price on shares of Revvity from $130.00 to $141.00 and gave the stock a "buy" rating in a research note on Tuesday, July 30th. Eight analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Revvity has a consensus rating of "Moderate Buy" and a consensus target price of $123.81.

Revvity Stock Up 1.6 %

Shares of RVTY traded up $1.86 during trading hours on Friday, hitting $121.25. The company had a trading volume of 578,662 shares, compared to its average volume of 857,791. The firm has a fifty day moving average price of $112.81 and a 200-day moving average price of $108.28. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.27. The stock has a market capitalization of $14.96 billion, a price-to-earnings ratio of 100.21, a P/E/G ratio of 2.97 and a beta of 1.05. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $128.15.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The business had revenue of $691.70 million during the quarter, compared to analyst estimates of $690.33 million. During the same quarter in the previous year, the firm earned $1.21 EPS. Revvity's revenue was down 2.5% on a year-over-year basis. On average, equities research analysts forecast that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date is Friday, October 18th. Revvity's dividend payout ratio (DPR) is 23.14%.

Insider Activity

In other news, insider Joel S. Goldberg sold 3,500 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the sale, the insider now owns 33,400 shares of the company's stock, valued at approximately $3,936,524. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Joel S. Goldberg sold 3,500 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the sale, the insider now owns 33,400 shares of the company's stock, valued at approximately $3,936,524. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joel S. Goldberg sold 4,000 shares of the company's stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $110.46, for a total transaction of $441,840.00. Following the sale, the insider now directly owns 36,900 shares of the company's stock, valued at approximately $4,075,974. The disclosure for this sale can be found here. Insiders own 0.60% of the company's stock.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.